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non-medical costs (i.e., physician visits, hospitalizations, and
special nurses/caregivers) were retrieved from a private hospital
in Thailand. Effectiveness was deﬁned as the improvement of 
the Alzheimer’s disease assessment scale-cognitive subscale
(ADAS-cog) scores. Effectiveness data and probabilities used in
the model were obtained from relevant published studies. Sensi-
tivity analyses were performed to determine the model robust-
ness. RESULTS: The cost-effectiveness analyses shows that
compared with no treatment, incremental cost of high dose-
rivastigmine costs the lowest for patients with Alzheimer’s
Disease to gain one point improvement of ADAS-cog score
[30,162 Baht ($754) per year], whereas the incremental cost of
donepezil was 32,362 ($809) Baht per year and low dose-
rivastigmine costs the highest [77,102 ($1928) Baht per year].
Sensitivity analyses shows that the model is robust. CONCLU-
SION: High dose-rivastigmine and donepezil are more cost-
effective compared with low dose-rivastigmine for patients with
Alzheimer’s Disease in Thailand.
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OBJECTIVE: Quetiapine has been shown to be effective in the
treatment of behavioral and psychological signs of dementia
(BPSD). This analysis evaluates the cost-effectiveness of treating
community-dwelling patients with Alzheimer’s disease (AD) and
BPSD in the US. METHODS: A discrete event simulation was
designed to track the symptoms of BPSD and the resulting inﬂu-
ence on costs, caregiver burden and institutionalization in indi-
viduals under two scenarios: treatment with quetiapine at 200
mg per day, and no treatment. The model is populated using data
from a randomized trial comparing quetiapine to placebo, a lon-
gitudinal cohort study in AD patients, US costing sources, and
the literature. Costs, reported in 2004 US dollars, are examined
from the perspective of a comprehensive health care payer and
society, and include doctor visits, nursing home stays, hospital-
ization, adult day care, home health care, caregiver time and que-
tiapine treatment. In the base case, a one year time horizon is
used. RESULTS: On average, untreated patients spend just over
60% of their time in the community with high levels of BPSD,
while caregivers spend an average of 5.7 hours per day caring
for patients. Per patient costs average $35,642, 77% of which
consists of informal caregiving costs. Quetiapine reduces the time
spent with high BPSD by 24 days, while caregiver time is reduced
by 76 hours per patient. A modest reduction in institutionaliza-
tion (9%) is also predicted. The net effect is an increase in direct
costs of $439 per patient ($6830 per high BPSD year avoided),
but savings of $738 from the societal perspective. A total of 96%
of replications resulted in quetiapine dominating no treatment
from the societal perspective. Results are particularly sensitive to
caregiver time valuation. CONCLUSIONS: Treatment with que-
tiapine has the potential to alleviate caregiver burden and can
lead to considerable savings from the societal perspective.
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OBJECTIVES: To identify changes in management levels and
costs for a cohort of nursing home residents admitted for
Alzheimer’s disease (AD) over a six-year period. METHODS:
Long-term care data from Minnesota for 1995 through 2000
were examined. Nurses from Minnesota’s Quality Assurance and
Review Program evaluate care needs of nursing home residents
annually. Residents are classiﬁed according to dependence level
in each of eight activities of daily living (ADL). This ADL assess-
ment and other factors establish the management level and reim-
bursement rate for care. AD cases were identiﬁed using ICD-9
principal diagnosis codes and personal identiﬁers. Only patients
with AD who were residents throughout the six years were 
analyzed. Nursing home reimbursement rates for 2002 were
obtained from Minnesota’s Department of Human Services. Cost
estimates include nursing and ancillary staff care, and room and
board. Costs are reported in 2002 US$. RESULTS: Of the 2382
assessed patients with AD identiﬁed in 1995, 382 qualiﬁed for
this analysis. Of those, 90% were female and the mean age was
81 years (range: 56–101). Behavior problems were noted in 71%
in 1995 and 2000. In 1995, 25% received an antipsychotic agent
regularly. This rate decreased each year and was 15% by 2000.
The proportion of residents in low and medium dependency
levels decreased from 59% to 16% over six years; whereas, the
high dependency group rose from 41% to 84%. In 2000, sig-
niﬁcantly (p = 0.000) more residents were assessed as physically
and mentally incapable of self-preservation than in 1995. On
average, this increase in care needs resulted in an additional
annual cost of $7273 per resident by the end of the six-year
period and roughly $2.6 million for the cohort. CONCLU-
SIONS: Patients with AD residing in nursing homes continue to
deteriorate over time, resulting in a substantial increase in care
needs and costs.
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OBJECTIVE: To examine the persistency rates and persistency
days of rivastigmine and donepezil in patients with Alzheimer’s
Disease (AD) and to determine predictors of persistency.
METHODS: This retrospective study used MarketScan®
research database during January 1, 1999–December 31, 2002.
The study identiﬁed 229 new users of rivastigmine and 554 new
users of donepezil (i.e., no use of cholinesterase inhibitor (ChEI)
during the 18 month-history period) who were newly diagnosed
with AD between July 1, 2000–June 30, 2001, were at least 65
years old, and had continuous health/prescription insurance.
Patients who reﬁlled their initial ChEI prescription within a per-
missible gap of 60 days after depleting the drug supply from 
the prior prescription were considered to be persistent and the
robustness of the persistency deﬁnition was tested using sensi-
tivity analysis. Kaplan-Meier method and Cox proportional
hazard models were performed to examine the trends of persis-
tency and to identify factors that signiﬁcantly inﬂuenced persis-
tency. RESULTS: During the 1-year follow-up period, 53% of
rivastigmine and donepezil users discontinued or switched their
medications. Discontinuation was more common in donepezil-
users (43%) than in rivastigmine-users (37%), but switching
occurred more frequently in rivastigmine users (16% vs. 10%).
Rivastigmine-users continuously used their medication for an
average of 234 days while donepezil-users for 235 days (p =
0.91). Results were stable with variations in the deﬁnition of con-
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tinuous therapy. The risk of discontinuation/switching was not
statistically different between the two groups. Patients who used
a CNS medication before initiation of therapy, did not visit their
physician ofﬁce frequently or were not hospitalized after initia-
tion of ChEI therapy were more likely to discontinue/switch their
initial ChEI. CONCLUSION: Levels of persistency among the
elderly patients with AD is similar between rivastigmine and
donepezil in a real-world setting. Further research is needed to
determine ways of improving persistency and to estimate the
long-term economic impact of persistency with ChEIs on AD
treatment costs.
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OBJECTIVES: Recent research has shown that antidepressants
may improve non-cognitive symptoms in patients with
Alzheimer’s disease (AD). The economic beneﬁts of antidepres-
sant use in this population are unknown. This study investigated
whether antidepressants use by AD patients could delay the
admission to long-term care (LTC) treatment and reduce total
costs. METHODS: Patients diagnosed with AD from 1995–2001
were retrieved from a 20% sample of the California Medicaid
(Medi-Cal) claims database. The index date for the antidepres-
sant group was deﬁned as the dispensing date of ﬁrst antide-
pressant medication, and for the control group, it was deﬁned 
as the date of initial AD diagnosis. Generalized linear models
(GLM) with log link function and gamma distribution were
applied to compare the ﬁrst year total post-index medical (non-
pharmacy) costs and the total health care costs between the
groups, controlling for demographics, comorbidities, and prior
utilization. Cox proportional hazard regression was used to
model the time to ﬁrst LTC admission since index date, adjust-
ing for the same set of covariates. RESULTS: In total, 3515 AD
patients were identiﬁed, with 1645 in the antidepressant group
and 1870 in the control. AD patients with antidepressants were
younger (77 vs. 80 years, p < 0.0001), had higher proportion of
Caucasians (57% vs. 53%, p < 0.0001), and had a similar
comorbidity proﬁle as the control group. Adjusted for potential
confounders, the GLM estimates showed that using antidepres-
sants was related to 40% and 36% lower post-index total
medical costs and total health care costs (p < 0.0001 for both),
respectively. In the Cox regression, antidepressant group had
34% lower risk of admission to LTC than the control group 
(P < 0.0001). CONCLUSIONS: In this study, antidepressant use
in AD patients associated a signiﬁcant reduction in total costs
and appeared to postpone long-term care admission.
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OBJECTIVES: Although acetylcholinesterase inhibitors (AChEI)
are the only class of drugs indicated for Alzheimer’s disease (AD),
drugs treating non-cognitive symptoms and drugs possibly ben-
eﬁcial to cognitive functions (e.g. estrogen, selegiline) are also
prescribed for AD patients in practice. This study investigated 1)
Characteristics of physicians giving the initial AD diagnosis; 2)
prescription choice and patterns for AD in a Medicaid popula-
tion. METHODS: AD Patients with a minimum of 12 months
continuous eligibility after initial diagnosis of AD were identi-
ﬁed from a 20% Medi-Cal claims database of 1995–2002.
During the ﬁrst year follow-up, the prescription claims of the 
following drug classes were analyzed: AChEI, antidepressants,
antianxiety agents, antipsychotics, estrogen and antiparkinson-
ian MAO inhibitor (e.g. selegiline). Regression models were
applied to study the prescription pattern. RESULTS: A total of
4386 AD patients were initially diagnosed by 2205 unique physi-
cians. Among 1055 AD patients diagnosed by physicians with
specialty information, 35.5% were diagnosed by primary care
physicians (PCPs), 22.6% by internists, 19.4% by neurologists,
4.3% by psychiatrist, and the rest by other specialists. During
the ﬁrst year of follow up, 42.5% patients did not receive any
AD-related medications. Controlling for demographics, diagno-
sis year and comorbidities, patients diagnosed by PCPs were least
likely to get any prescription compared to neurologists (OR =
1.64, p = 0.01), and psychiatrists (OR = 2.22, p = 0.0065).
Antipsychotics were the most frequently prescribed drugs
(34.0% patients), followed by antidepressants (27.2%), and
antianxiety agents (16.1%). Only 22.3% of patients diagnosed
after 1997, when AChEI became available, received drugs in this
class. 27.5% patients received more than one class of drugs.
From 1995–2002, drug treatment was increasing for all classes
except estrogen and selegiline. CONCLUSIONS: Although use
of medications increased over years, patients with AD seemed to
be under-treated, especially those diagnosed by PCPs. Contrary
to guideline recommendations, most treated patients only
received drugs for non-cognitive symptoms.
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The feasibility and accuracy of obtaining patient reported out-
comes electronically, particularly from elderly subjects, has been
questioned. OBJECTIVE: To pilot the use of a telephone-based
Interactive Voice Response Data Entry System (IVRS) by elderly
caregivers of patients with Alzheimer’s Disease. METHODS:
Caregivers were trained by nurses to record patient and caregiver
health care utilization data into a 30-day diary and to enter these
data using IVRS. The system was accessed via a toll-free tele-
phone number using a unique subject identiﬁer. Caregivers had
15 minutes to read detailed training notes in the waiting room.
Feasibility and accuracy parameters assessed were time to train,
time to enter the data and accuracy of hypothetical diary data
entry. RESULTS: Time to train the caregiver (60% women, 52
to 80+ years old) on both the use of the diary and IVRS data
entry ranged from 36 to 48 minutes. Thirty days of hypotheti-
cal diary data provided to the patient for the exercise were
entered via IVRS in 8 to 12 minutes per subject. No signiﬁcant
difﬁculties were observed with any caregiver and only one data
point by one caregiver was incorrectly entered. IVRS features
such as question repeat, invalid answer prompt, and automatic
re-entry to last question answered if entry was interrupted all
worked well. Caregivers expressed their willingness to use the
diary daily and to enter data every 30 days over the planned 18-
